Constipation Clinical Trial
| NCT number | NCT02819297 |
| Other study ID # | BLI400-302 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | June 2016 |
| Est. completion date | June 2017 |
| Verified date | July 2020 |
| Source | Braintree Laboratories |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The objective of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus placebo in constipated adults.
| Status | Completed |
| Enrollment | 1020 |
| Est. completion date | June 2017 |
| Est. primary completion date | June 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Male or female subjects at least 18 years of age 2. Constipated, defined by the following adapted ROME II definition Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months: - Straining during > 25% of defecations - Lumpy or hard stools in > 25% of defecations - Sensation of incomplete evacuation for > 25% of defecations 3. If female, and of child-bearing potential, is using an acceptable form of birth control 4. Negative serum pregnancy test at screening, if applicable 5. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: 1. Report loose (mushy) or water stools in the absence of laxative use for more than 25% of BMs during the 12 weeks before Visit 1 2. Meet the Rome II criteria for Irritable Bowel Syndrome. 3. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon 4. Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1 5. Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1 6. Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of the study 7. Subjects who are pregnant or lactating, or intend to become pregnant during the study 8. Subjects of childbearing potential who refuse a pregnancy test 9. Subjects who are allergic to any study medication component 10. Subjects taking narcotic analgesics or other medications known to cause constipation 11. Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG 12. Subjects with clinically significant laboratory abnormalities, deemed as a potential safety issue by the Investigator 13. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures 14. Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days 15. Subjects with an active history of drug or alcohol abuse 16. Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1 17. Subjects who withdraw consent at any time prior to completion of Visit 1 procedures |
| Country | Name | City | State |
|---|---|---|---|
| United States | Braintree Research Site 11 | Anaheim | California |
| United States | Braintree Research Site 41 | Atlanta | Georgia |
| United States | Braintree Research Site 7 | Bastrop | Louisiana |
| United States | Braintree Research Site 8 | Birmingham | Alabama |
| United States | Braintree Research Site 26 | Brooklyn | New York |
| United States | Braintree Research Site 22 | Chattanooga | Tennessee |
| United States | Braintree Research Site 15 | Chicago | Illinois |
| United States | Braintree Research Site 16 | Cincinnati | Ohio |
| United States | Braintree Research Site 45 | Clearwater | Florida |
| United States | Braintree Research Site 30 | Cleveland | Ohio |
| United States | Braintree Research Site 48 | Columbus | Ohio |
| United States | Braintree Research Site 29 | Corona | California |
| United States | Braintree Research Site 9 | Dayton | Ohio |
| United States | Braintree Research Site 36 | Denver | Colorado |
| United States | Braintree Research Site 35 | Garden Grove | California |
| United States | Braintree Research Site 17 | Hartsdale | New York |
| United States | Braintree Research Site 10 | Hialeah | Florida |
| United States | Braintree Research Site 37 | Hialeah | Florida |
| United States | Braintree Research Site 39 | Hialeah | Florida |
| United States | Braintree Research Site 21 | High Point | North Carolina |
| United States | Braintree Research Site 40 | Houston | Texas |
| United States | Braintree Research Site 31 | Knoxville | Tennessee |
| United States | Braintree Research Site 32 | La Mirada | California |
| United States | Braintree Research Site 23 | Lancaster | South Carolina |
| United States | Braintree Research Site 24 | Las Vegas | Nevada |
| United States | Braintree Research Site 4 | Little Rock | Arkansas |
| United States | Braintree Research Site 20 | Marietta | Georgia |
| United States | Braintree Research Site 46 | Meridian | Idaho |
| United States | Braintree Research Site 2 | Miami | Florida |
| United States | Braintree Research Site 38 | Miami | Florida |
| United States | Braintree Research Site 52 | Miami | Florida |
| United States | Braintree Research Site 6 | Miami | Florida |
| United States | Braintree Research Site 19 | Miami Lakes | Florida |
| United States | Braintree Research Site 44 | Miami Springs | Florida |
| United States | Braintree Research Site 47 | Mobile | Alabama |
| United States | Braintree Research Site 12 | New Orleans | Louisiana |
| United States | Braintree Research Site 14 | Newport News | Virginia |
| United States | Braintree Research Site 49 | Norfolk | Virginia |
| United States | Braintree Research Site 13 | Orlando | Florida |
| United States | Braintree Research Site 43 | Pembroke Pines | Florida |
| United States | Braintree Research Site 28 | Phoenix | Arizona |
| United States | Braintree Research Site 5 | Raleigh | North Carolina |
| United States | Braintree Research Site 50 | Sacramento | California |
| United States | Braintree Research Site 34 | San Antonio | Texas |
| United States | Braintree Research Site 18 | Smithfield | Pennsylvania |
| United States | Braintree Research Site 27 | Snellville | Georgia |
| United States | Braintree Research Site 25 | Tamarac | Florida |
| United States | Braintree Research Site 3 | Tampa | Florida |
| United States | Braintree Research Site 42 | West Jordan | Utah |
| United States | Braintree Research Site 1 | West Palm Beach | Florida |
| United States | Braintree Research Site 51 | Westminster | California |
| Lead Sponsor | Collaborator |
|---|---|
| Braintree Laboratories |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Treatment Response | The primary endpoint is the proportion of subjects who are weekly responders for at least 9 out of 12 weeks, with at least 3 of these weeks occurring in the last 4 weeks of treatment. A weekly responder is a subject who has = 3 CSBMs and an increase from baseline of > 1 CSBM in that week. | 12 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
| Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
| Recruiting |
NCT05734833 -
Do Probiotics Improve Recovery From Acute Constipation in Kids?
|
N/A | |
| Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
| Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
| Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
| Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
| Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
| Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
| Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
| Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
| Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
| Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
| Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
| Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
| Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
| Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
| Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
| Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |